Clinical Trial Update: Cystatin and Early AKI Detection Contrast Induced Acute Kidney Injury

View source ↗

Summary

This clinical trial is investigating cystatin as an early detection biomarker for contrast-induced acute kidney injury, with recruitment currently ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Injury

Snippet

Sponsor: BayCare Health System | Conditions: Acute Kidney Injury | Status: RECRUITING